Secretory Carcinoma of the Thyroid Gland: Report of a Highly Aggressive Case Clinically Mimicking Undifferentiated Carcinoma and Review of the Literature.
Anaplastic carcinoma
ETV6 gene rearrangement
Mammary analogue secretory carcinoma
Papillary carcinoma
Thyroid
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
04
08
2018
accepted:
10
12
2018
pubmed:
20
12
2018
medline:
18
4
2020
entrez:
20
12
2018
Statut:
ppublish
Résumé
After being described in the salivary glands as a malignancy with features essentially identical to those of the breast, secretory carcinoma (SC) (formerly mammary analogue SC) has now been identified in other sites including the skin, lung, and thyroid gland. In the breast, SC has a relatively favorable prognosis. Likewise when arising in the salivary glands, it is generally considered to be a low to intermediate grade carcinoma; however, there is a range of clinical behavior with occasional patients dying of progressive disease. SCs of the thyroid gland are rare, and reports suggest a relatively aggressive behavior, at least relative to well differentiated carcinomas such as papillary carcinoma and minimally invasive follicular carcinoma. We present a patient with a highly aggressive thyroid gland SC that mimicked undifferentiated carcinoma clinically. The patient had widespread metastatic disease and died rapidly from airway compromise. We also review the literature for reported cases of thyroid gland SC in order to better establish the clinical features and expected clinical course of such tumors occurring at this site.
Identifiants
pubmed: 30564997
doi: 10.1007/s12105-018-0995-2
pii: 10.1007/s12105-018-0995-2
pmc: PMC6854196
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
562-572Références
Lakhani SR, Ellis IO, Schnitt SJ, WHO classification of tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2012.
McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966;195:388.
doi: 10.1001/jama.1966.03100050096033
Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. Cancer. 1980;45:2404–13.
doi: 10.1002/1097-0142(19800501)45:9<2404::AID-CNCR2820450928>3.0.CO;2-8
Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011;135:1606–10.
doi: 10.5858/arpa.2010-0351-RS
Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.
pubmed: 20410810
Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11:55–67.
doi: 10.1007/s12105-017-0795-0
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO classification of head and neck tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012;61:387–94.
doi: 10.1111/j.1365-2559.2012.04232.x
Skálová A, Vanecek T, Majewska H, Laco J, Grossman P, Simpson RH, et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38:23–33.
doi: 10.1097/PAS.0000000000000088
Bishop JA, Taube JM, Su A, Binder SW, Kaxakov DV, Michal M, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions: a cutaneous analogue to secretory carcinomas of the breast and salivary glands. Am J Surg Pathol. 2017;41:62–6.
doi: 10.1097/PAS.0000000000000734
Hyrcza MD, Ng T, Crawford RI. Detection of the ETV6-NTRK3 translocation in cutaneous mammary-analogue secretory carcinoma. Diagn Histopathol. 2015;21:481–84.
doi: 10.1016/j.mpdhp.2015.10.003
Huang T, McHugh JB, Berry GJ, Myers JL. Primary mammary analogue secretory carcinoma of the lung: a case report. Hum Pathol. 2018;74:109–13.
doi: 10.1016/j.humpath.2017.10.027
Nguyen JK, Bridge JA, Joshi C, McKenney JK. Primary mammary analog secretory carcinoma (MASC) of the vulva with ETV6-NTRK3 fusion: a case report. Int J Gynecol Pathol. 2018.
Baneckova M, Agaimy A, Andreasen S, Vanecek T, Steiner P, Slouka D, et al. Mammary analog secretory carcinoma of the nasal cavity: characterization of 2 cases and their distinction from other low-grad sinonasal adenocarcinomas. Am J Surg Pathol. 2018;42:735–43.
doi: 10.1097/PAS.0000000000001048
Lurquin E, Jorissen M, Debiec-Rychter M, Hermans R, Hauben E. Mammary analogue secretory carcinoma of the sinus ethmoidalis. Histopathology. 2015;67:749–51.
doi: 10.1111/his.12702
Stevens TM, Kovalovsky AO, Velosa C, Shi Q, Dai Q, Owen RP, et al. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol. 2015;2864:1084–100.
doi: 10.1038/modpathol.2015.64
Reynolds S, Shaheen M, Olson G, Barry M, Wu J, Bocklage T. A case of primary mammary analog secretory carcinoma (MASC) of the thyroid masquerading as papillary thyroid carcinoma: potentially more than a one off. Head Neck Pathol. 2016;10:405–13.
doi: 10.1007/s12105-016-0715-8
Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol. 2016;29:985–95.
doi: 10.1038/modpathol.2016.115
Dettloff J, Seethala RR, Stevens TM, Brandwein-Gensler M, Centeno BA, Otto K, et al. Mammary analog secretory carcinoma (MASC) involving the thyroid gland: a report of the first 3 cases. Head Neck Pathol. 2016;11:124–30.
doi: 10.1007/s12105-016-0741-6
Rupp AP, Bocklage TJ. Mammary analog secretory carcinoma of thyroid: a case report. Diagn Cytopathol. 2017;45:45–50.
doi: 10.1002/dc.23608
Lei Y, Chiosea SI. Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools. Head Neck Pathol. 2012;6:166–70.
doi: 10.1007/s12105-011-0312-9
Majewska H, Skálová A, Stodulski D, Klimkova A, Steiner P, Stankiewicz C, et al. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch. 2015;466:245–54.
doi: 10.1007/s00428-014-1701-8
Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21:350–3.
doi: 10.1016/j.breast.2012.02.013
Bishop JA, Taube JM, Su A, Binder SW, Kazakov DV, Michal M, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions: a cutaneous analogue to secretory carcinomas of the breast and salivary glands. Am J Surg Pathol. 2017;41:62–6.
doi: 10.1097/PAS.0000000000000734
Wu EY, Lebastchi J, Marqusee E, Lorch JH, Krane JF, Barletta JA. A case of primary secretory carcinoma of the thyroid with high-grade features. Histopathology. 2017;71:665–69.
doi: 10.1111/his.13268
Liao H, Khan A, Miron PM, Cornejo KM. Mammary analogue secretory carcinoma of the thyroid mimicking locally advanced papillary thyroid carcinoma: a rare case report. Int J Surg Pathol. 2018;26:459–63.
doi: 10.1177/1066896917747076
Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, et al. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014;124:188–95.
doi: 10.1002/lary.24254
Khalele BA. Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck. 2017;39:1243–48.
doi: 10.1002/hed.24755
Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013;7:35–9.
doi: 10.1007/s12105-013-0429-0
Simpson RHW, Bacani J, Skalova A. (2018) United States and Canadian Academy of Pathology evening speciality conference—head, neck, & endocrine pathology. In: Evening speciality conference: challenging cases and concepts in head and neck and endocrine pathology. Vancouver, BC, Canada.
Krausz T, Jenkins D, Grontoft O, Pollock DJ, Azzopardi JG. Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis. Histopathology. 1989;14:25–36.
doi: 10.1111/j.1365-2559.1989.tb02111.x
Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011;6:19.
doi: 10.1186/1746-1596-6-19
Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–76.
doi: 10.1016/S1535-6108(02)00180-0
Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sata Y, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999;93:1355–63.
doi: 10.1182/blood.V93.4.1355
Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, Kozakewich HP, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451–8.
doi: 10.1016/S0002-9440(10)65732-X
Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–7.
doi: 10.1038/ng0298-184
Seethala RR, Chiosea SI, Liu CZ, et al. Clinical and morphologic features of ETV6-NTRK3 translocated papillary thyroid carcinoma in an adult population without radiation exposure. Am J Surg Pathol. 2016;41:446–57.
doi: 10.1097/PAS.0000000000000814
Ito Y, Ishibashi K, Masaki A, Fujii K, Fujiyoshi Y, Hattori H, et al. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. Am J Surg Pathol. 2015;39:602–10.
doi: 10.1097/PAS.0000000000000392
Skálová A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol. 2016;40:3–13.
doi: 10.1097/PAS.0000000000000537
Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016. https://doi.org/10.1002/cncr.29887 .
doi: 10.1002/cncr.29887
pubmed: 26784937
Otsubo R, Mussazhanova Z, Akazawa Y, et al. Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature. J Pediatr Endocrinol Metab. 2018;31:461–7.
doi: 10.1515/jpem-2017-0292
Skalova A, Vanecek T, Martinek P, Weinreb I, Stevens TM, Simpson RHW, et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol. 2018;42:234–46.
doi: 10.1097/PAS.0000000000000972
Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920–6.
doi: 10.1093/annonc/mdw042